Bayer AG (BAYRY) announced that the late-stage studies on the investigational compound elinzanetant were successful.Elinzanetant is the first dual neurokinin-1,3 receptor antagonist in late-stage clinical development for the non-hormonal treatment of moderate to severe vasomotor symptoms (“VMS”), also known as hot flashes associated with menopause, administered orally once daily.The phase III studies, OASIS 1 and 2 are double-blind, randomized, placebo-controlled multicenter studies investigating the effica ...